AGIO
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- FDA granted Priority Review to Agios' supplemental NDA for mitapivat in sickle cell diseaseJul 8, 2026
- Agios provided an update on the Phase 2b tebapivat trial in lower-risk myelodysplastic syndromesMay 29, 2026
- PYRUKYND receives European Union approval for adults with thalassemiaMay 23, 2026
- Agios partner Avanzanite announces EU approval of PYRUKYND for adults with thalassemiaMay 23, 2026
- Agios submitted an sNDA to the FDA seeking accelerated approval of Mitapivat for sickle cell diseaseMay 13, 2026